NASDAQ:NPCE NeuroPace Q3 2026 Earnings Date & Estimates $12.80 -0.32 (-2.44%) As of 02:17 PM Eastern This is a fair market value price provided by Massive. Learn more. NeuroPace is estimated to report Q3 2026 earnings on Thursday, November 12, 2026, after market closes. The conference call is scheduled for 4:30 PM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 12, 2026TimeAfter Market ClosesConference Call4:30 PM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from NeuroPace in Q3 2026NeuroPace is expected to post earnings of -$0.1088 per share on revenue of $27.13 million. In the same quarter a year earlier NeuroPace reported -$0.11 per share on revenue of $27.35 million. NeuroPace last reported on August 11, 2026, posting -$0.18 per share and beating the -$0.2179 consensus estimate. NeuroPace has beaten the consensus EPS estimate in 7 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.1088Expected Revenue$27.13 millionPrior-Year EPS-$0.11Prior-Year Revenue$27.35 millionExpected Revenue Growth-0.8%Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.18 (Beat by +$0.0379)Last Quarter Revenue$22.83 millionEPS Beat Rate7 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report NeuroPace Q3 2026 Earnings FAQ When does NeuroPace report Q3 2026 earnings? NeuroPace (NASDAQ:NPCE) is estimated to report Q3 2026 earnings on Thursday, November 12, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it. What time is NeuroPace's Q3 2026 earnings call? NeuroPace's Q3 2026 earnings conference call is scheduled for Thursday, November 12, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for NeuroPace? Analysts expect NeuroPace to post earnings of -$0.1088 per share for Q3 2026. How much revenue is NeuroPace expected to report? The consensus revenue estimate for NeuroPace is $27.13 million for Q3 2026. NeuroPace Earnings HeadlinesNeuroPace to Report Third Quarter 2026 Financial Results on November 12, 2026October 29, 2026 | finance.yahoo.comKeyBanc Initiates NeuroPace at Overweight With $18 Price TargetSeptember 18, 2026 | marketscreener.comMA free stock pick, from me to youElon's paid this chip supplier since 2012. When NVIDIA tried to buy the company, he fought the deal. Without its chip, his AI satellites don't fly. Now he wants 1,000,000 of them in orbit, 100 times what's up there today, and every one pays this company a royalty. Dylan believes shares could react by December 8th.November 10 at 1:00 AM | Behind the Markets (Ad)NeuroPace to Participate in 2026 Cantor Global Healthcare ConferenceSeptember 1, 2026 | businesswire.comNeuroPace to Participate in Wells Fargo 21st Annual Healthcare ConferenceAugust 31, 2026 | businesswire.comNeuroPace, Inc. (NPCE) Q2 2026 Earnings Call TranscriptAugust 14, 2026 | seekingalpha.comSee More NeuroPace Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like NeuroPace? Sign up for Earnings360's daily newsletter to receive timely earnings updates on NeuroPace and other key companies, straight to your email. Email Address About NeuroPaceNeuroPace (NASDAQ:NPCE) is a medical device company focused on developing and commercializing therapies for people with drug-resistant epilepsy. Its principal product is the RNS System, an implantable responsive neurostimulation device designed to detect abnormal electrical activity in the brain and deliver targeted stimulation intended to prevent or reduce seizures. The RNS System includes an implanted neurostimulator, leads placed at or near seizure-onset areas, and a programming and data-management platform used by healthcare professionals. The system continuously monitors brain activity and records relevant neurological data, which can help physicians personalize treatment and evaluate patient response over time. NeuroPace was founded in 1997 and received U.S. Food and Drug Administration approval for the RNS System in 2013. The company is headquartered in Mountain View, California, and primarily serves patients and healthcare providers in the United States through specialized epilepsy centers. Its activities also include clinical research and the development of software and related technologies intended to support epilepsy care.View NeuroPace ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles DraftKings Just Lost 20%—And Its Biggest Gamble Is Still AheadBarrick's Earnings Beat Could Be Overshadowed by an Even Bigger OpportunityAxon vs. Motorola: Which Public Safety Stock Has More Upside After Q3 Earnings?Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?Wall Street May Be Making a Big Mistake With monday.com StockCloudflare's 20% Sell-Off May Have Created an Opening for InvestorsMarketBeat Week in Review – 11/2 - 11/6 Upcoming Earnings Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026)Cisco Systems (11/12/2026)Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
